Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age
- PMID: 19450636
- DOI: 10.1016/j.vaccine.2009.05.023
Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age
Abstract
In October 2003 the Advisory Committee on Immunization Practices (ACIP) recommended influenza vaccination for all children ages 6-23 months. We evaluated the safety of this recommendation by querying the Vaccine Adverse Events Reporting System (VAERS) for serious adverse events (SAE) reported between July 1, 2003 and June 30, 2006 in 6-23 month old infants after trivalent inactivated influenza vaccine (TIV). Cases were reviewed and the causal relationship with vaccine assessed. One hundred and four SAE were reported; median time from vaccination to SAE onset was one day. The two most commonly reported SAE disease categories were fever (N=52) and seizure (N=35). Causality assessment revealed that none of the SAE was definitely related to TIV. Although the number of SAE increased over time, the most common types of events remained unchanged with no new or unexpected safety concerns identified with expanded TIV use.
Similar articles
-
Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children: Analysis of the Vaccine Adverse Event Reporting System.Pediatr Infect Dis J. 2011 Jan;30(1):e1-8. doi: 10.1097/INF.0b013e3181ff9795. Pediatr Infect Dis J. 2011. PMID: 21042229 Review.
-
Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.MMWR Morb Mortal Wkly Rep. 2009 Dec 11;58(48):1351-6. MMWR Morb Mortal Wkly Rep. 2009. PMID: 20010511
-
Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study.Pediatr Infect Dis J. 2010 Feb;29(2):105-10. doi: 10.1097/INF.0b013e3181b84c34. Pediatr Infect Dis J. 2010. PMID: 19934787 Clinical Trial.
-
Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003.Pediatrics. 2005 Feb;115(2):453-60. doi: 10.1542/peds.2004-1519. Pediatrics. 2005. PMID: 15687455
-
Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).Pharmacoepidemiol Drug Saf. 2004 Dec;13(12):825-40. doi: 10.1002/pds.936. Pharmacoepidemiol Drug Saf. 2004. PMID: 15386719 Review.
Cited by
-
COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review.Front Immunol. 2022 Jul 5;13:872683. doi: 10.3389/fimmu.2022.872683. eCollection 2022. Front Immunol. 2022. PMID: 35865539 Free PMC article. Review.
-
Acute Fulminant Myocarditis Following Influenza Vaccination Requiring Extracorporeal Membrane Oxygenation.Acute Crit Care. 2019 May;34(2):165-169. doi: 10.4266/acc.2017.00045. Epub 2018 Nov 7. Acute Crit Care. 2019. PMID: 31723923 Free PMC article.
-
The Saudi Thoracic Society guidelines for influenza vaccinations.Ann Thorac Med. 2015 Oct-Dec;10(4):223-30. doi: 10.4103/1817-1737.167065. Ann Thorac Med. 2015. PMID: 26664559 Free PMC article.
-
Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine.BMJ Open. 2011 May 30;1(1):e000016. doi: 10.1136/bmjopen-2010-000016. BMJ Open. 2011. PMID: 22021725 Free PMC article.
-
Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination.Vaccine. 2011 Oct 26;29(46):8302-8. doi: 10.1016/j.vaccine.2011.08.093. Epub 2011 Sep 3. Vaccine. 2011. PMID: 21893148 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
